Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
30 avr. 2024 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
Dyadic to Attend Industry Events in April
27 mars 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
21 mars 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
02 janv. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™
19 sept. 2023 08h00 HE
|
Dyadic International, Inc.
Dyadic to receive upfront payment of $0.6 million for product development and licensing its Dapibus™ platform, in addition to potential success fees, milestones, and royalties. JUPITER, Fla., Sept. ...
Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
10 mai 2023 16h00 HE
|
Dyadic International, Inc.
New research collaboration with a Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human healthExpanded licensing agreement with Rubic One Health (“Rubic”) to develop,...
Dyadic to Participate at Two Industry Events in May
10 mai 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
26 avr. 2023 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023
15 mars 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 15, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic to Present at Roth Investor Conference and Upcoming Industry Events
01 mars 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...